1 Enterprise Drive
Shelton, CT 06484
Intensity Therapeutics is a clinical-stage biotechnology company whose mission is to help patients live longer, higher quality lives by discovering, developing, and commercializing first-in-class cancer drugs that attenuate tumors with minimal side effects, while igniting the patient’s immune system to fight the cancer. Our lead product candidate, INT230-6, has been tested in ~200 patients in human clinical studies to treat refractory solid cancers.
Background and Key Achievements
We have late-stage pipeline programs in metastatic and presurgical settings with multiple near-term inflexion points. We have a robust IP portfolio, a platform validated through multiple Industry, government and university hospital partnerships, positive data that led to partnerships with Merck, Bristol Myers Squibb, and the National Institute of Health. Recently we completed an oversubscribed, top-of-range initial public offering on the NASDAQ exchange, raising ~$22.5 million. The ticker is INTS.